India to United States: Amlodipine Export Trade Route

To import Amlodipine formulations into the United States, the following approvals and registrations are mandatory:

• New Drug Application (NDA) or Abbreviated New Drug Application (ANDA): Manufacturers must submit either an NDA for new drugs or an ANDA for generic drugs to the FDA. These applications should be formatted in the Common Technical Document (CTD) or electronic CTD (eCTD) format.

• Establishment Registration and Drug Listing: Foreign manufacturers are required to register their establishments with the FDA and list all drug products intended for commercial distribution in the U.S.

• Labeling Compliance: Product labeling must meet FDA requirements, including accurate representation of the drug's identity, strength, quality, and purity.

• Importation Procedures: Importers must ensure compliance with FDA's import regulations, including prior notice of shipment and adherence to customs procedures.

Indian manufacturers exporting Amlodipine formulations to the United States must comply with the following Good Manufacturing Practice (GMP) standards:

• FDA GMP Compliance: Manufacturing facilities must adhere to the FDA's Current Good Manufacturing Practice (cGMP) regulations to ensure product quality and safety.

• FDA Inspections: The FDA conducts inspections of foreign manufacturing facilities to verify compliance with cGMP standards. Non-compliance can result in import alerts or refusal of product entry into the U.S.

• Recent Inspections and Regulatory Actions: The FDA has increased scrutiny of Indian pharmaceutical manufacturers in recent years. For instance, in April 2019, the FDA issued a statement regarding the presence of nitrosamine impurities in certain angiotensin II receptor blockers (ARBs), leading to recalls and heightened inspections of manufacturing facilities.

Between 2024 and 2026, several regulatory developments have impacted Indian pharmaceutical exports to the United States:

• Enhanced Inspection Protocols: In March 2025, the FDA implemented more stringent inspection protocols for foreign manufacturing facilities, focusing on data integrity and quality control measures.

• Mutual Recognition Agreements (MRAs): In January 2026, the FDA and India's Central Drugs Standard Control Organization (CDSCO) signed an MRA to streamline the inspection process and reduce regulatory burdens for compliant manufacturers.

• Policy Shifts: In June 2025, the FDA updated its guidance on nitrosamine impurities, requiring manufacturers to implement more rigorous testing and control strategies to ensure product safety.

These developments underscore the importance of maintaining high-quality manufacturing practices and staying informed about regulatory changes to ensure uninterrupted access to the U.S. market.

As of 2025, the United States Amlodipine market is valued at approximately $9.07 billion, with projections indicating growth to $10.24 billion by 2026. This growth is driven by the high prevalence of hypertension and cardiovascular diseases, an aging population, and substantial healthcare expenditures. The U.S. healthcare system's extensive coverage and emphasis on managing chronic conditions further bolster demand for antihypertensive medications like Amlodipine. While the United States has a robust pharmaceutical manufacturing sector, it also relies on imports to meet domestic demand. In 2024, the U.S. imported $79.5 billion worth of medicaments under HS code 300490, with India being a significant supplier, contributing $10.8 billion to this total.

Pharmaceutical products under HS code 30049072, including Amlodipine formulations, are subject to a 0% import duty rate in the United States under the MFN status. There are no additional tariffs, Value-Added Tax (VAT), or Goods and Services Tax (GST) imposed on these imports. The United States and India do not have a Free Trade Agreement (FTA) that affects pharmaceutical tariffs, and there are no anti-dumping duties currently applied to Amlodipine imports from India.

In addition to India, other major suppliers of Amlodipine formulations to the United States include Switzerland, Ireland, China, and Slovenia. In 2024, Switzerland exported $11.6 billion worth of medicaments under HS code 300490 to the U.S., while India contributed $10.8 billion. India's competitive pricing, driven by a large generic pharmaceutical industry and cost-effective manufacturing processes, positions it favorably against competitors like China and European manufacturers. This pricing advantage, coupled with the high quality of Indian pharmaceutical products, has solidified India's role as a key supplier in the U.S. Amlodipine market.

India is a global leader in the production of generic pharmaceuticals, accounting for approximately 20% of global generic medicine exports by volume. This extensive manufacturing capability extends to finished dosage forms containing Amlodipine, including tablets, capsules, and syrups. The country's cost-effective production is attributed to economies of scale, a skilled workforce, and a well-established supply chain. As of 2024, India hosts 396 facilities approved by the U.S. Food and Drug Administration (FDA), encompassing both Active Pharmaceutical Ingredients (API) and Finished Dosage Forms (FDF) manufacturing. This robust infrastructure ensures compliance with international quality standards, making India a preferred source for Amlodipine formulations globally.

When comparing Amlodipine formulation exports, India offers a competitive advantage over China and the European Union (EU) in terms of cost and quality. In 2024, the average unit price for generic oral solid formulations in the United States was $0.19, while in India, it was $0.13, indicating a cost-effective production model. Indian manufacturers are known for their adherence to stringent regulatory standards, with numerous facilities holding approvals from the FDA and the European Medicines Agency (EMA). This compliance ensures high-quality products that meet the regulatory requirements of the United States. Additionally, India's pharmaceutical industry has a strong track record of supply reliability, with established logistics and distribution networks facilitating consistent delivery of Amlodipine formulations.

The India-United States supply chain for Amlodipine formulations is characterized by substantial manufacturing capacity and reliable delivery. Indian facilities are equipped with advanced packaging and cold chain capabilities to maintain product integrity during transit. While there have been instances of regulatory scrutiny, such as the FDA's import alert on Sun Pharma's Halol facility in December 2022, these issues are typically addressed through corrective actions and facility upgrades. For example, Sun Pharma announced a $332 million investment in a new formulations manufacturing facility in Madhya Pradesh in December 2025 to enhance compliance and capacity. Overall, Indian manufacturers demonstrate a commitment to regulatory compliance and capacity expansion, ensuring a stable supply of Amlodipine formulations to the United States.

For United States buyers sourcing Amlodipine formulations from India, the following strategies are recommended:

• Implement a Dual-Sourcing Strategy: Engage with multiple Indian manufacturers to mitigate risks associated with supply disruptions and ensure continuity.

• Understand Minimum Order Quantities (MOQs): Indian suppliers may have varying MOQs; it's essential to negotiate terms that align with your demand forecasts and inventory management practices.

• Negotiate Favorable Payment Terms: Common payment terms in India-United States pharmaceutical trade include Letters of Credit (LC) and Telegraphic Transfers (TT). Establish clear agreements to facilitate smooth transactions.

• Conduct Thorough Supplier Qualification: Evaluate potential suppliers based on their regulatory approvals (e.g., FDA, WHO-GMP), manufacturing capabilities, quality control systems, and track record of compliance.

• Monitor Regulatory Compliance: Stay informed about any regulatory actions or updates concerning your suppliers to proactively address potential issues that may affect supply reliability.

By adhering to these guidelines, United States companies can effectively qualify Indian suppliers of Amlodipine formulations, ensuring compliance with regulatory standards and maintaining product quality and safety.